Healthcare / Medical DevicesHKSE
$1.45
+0.08 (+5.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-322.4M · quality 75.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$397M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-23.9%
↓Gross Margin
53.0%
↑Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.3%
FCF CAGR
—
FCF margin
-108.7%
FCF / Net income
1.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $233.3M · net income $-223.5M · FCF $-253.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $233.3M | $233.3M | $299.1M | $208.0M | $140.9M |
| Net Income | $-223.5M | $-223.5M | $-237.0M | $-191.7M | $-122.7M |
| EBITDA | $-165.7M | $-165.7M | $-195.3M | $-174.1M | $-117.7M |
| EPS | — | — | -0.90 | -0.70 | -0.50 |
| Gross Margin | 53.0% | 53.0% | 45.5% | 43.9% | 42.2% |
| Operating Margin | -90.8% | -90.8% | -89.9% | -117.0% | -154.9% |
| Net Margin | -95.8% | -95.8% | -79.2% | -92.2% | -87.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.37 | 0.37 | 0.29 | 0.20 | 0.05 |
| Current Ratio | 3.98 | 3.98 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-253.4M | $-253.4M | $-322.4M | $-371.4M | $-317.5M |
| Returns | |||||
| ROE | -23.9% | -23.9% | -20.7% | -13.7% | -7.7% |
| Valuation | |||||
| P/B | 0.42 | 0.42 | 0.64 | 0.47 | 0.66 |
| Growth & Yield | |||||
| Revenue Growth | -22.0% | -22.0% | 43.8% | 47.6% | — |
| EPS Growth | — | — | -28.6% | -40.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-49.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.90 → n/d
Residual
-49.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.